Substituted coumarins and quinolines and analogs as...

Details Substituted coumarins and quinolines and analogs as... Substituted coumarins and quinolines and analogs as...

2006-03-21

2006-03-21

Seaman, D. Margaret (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C546S157000, C546S167000, C546S283100, C514S312000, C514S291000, C514S307000, C514S314000, C514S422000, C514S444000, C514S456000, C548S517000, C549S315000, C549S013000, C549S399000

Reexamination Certificate

active

07015328

ABSTRACT:
The present invention is directed to substituted coumarins and quinolines and analogs thereof, represented by the general Formula I:wherein A, B, X, Y, and Z are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

REFERENCES:
patent: 5281619 (1994-01-01), Dell et al.
patent: 5284868 (1994-02-01), Dell et al.
patent: 5434160 (1995-07-01), Dell et al.
patent: 5514706 (1996-05-01), Ambler et al.
patent: 5571818 (1996-11-01), Williams
patent: 5574034 (1996-11-01), Williams
patent: 5576325 (1996-11-01), Williams
patent: 5624953 (1997-04-01), Ambler et al.
patent: 5637589 (1997-06-01), Lee et al.
patent: 5726204 (1998-03-01), Lee et al.
patent: 5847165 (1998-12-01), Lee et al.
patent: 6160010 (2000-12-01), Uckun et al.
patent: 6221900 (2001-04-01), Uckun et al.
patent: 6258824 (2001-07-01), Yang
patent: 6294575 (2001-09-01), Uckun et al.
patent: 6303652 (2001-10-01), Uckun et al.
patent: 6365626 (2002-04-01), Uckun et al.
patent: 6388092 (2002-05-01), Yang
patent: 2003/0065018 (2003-04-01), Cai et al.
patent: 0 537 949 (1993-04-01), None
patent: 0 599 514 (1994-06-01), None
patent: 0 618 206 (1994-10-01), None
patent: 0 619 314 (1994-10-01), None
patent: WO 99/54286 (1999-10-01), None
patent: WO 01/34591 (2001-05-01), None
Mohamed, CA 125:114568, 1995.
Woods, CA 60:45584, 1964.
Radwan, CA 124:117193, 1995.
Elgamal, CA 128:321530, 1998.
Tawada, CA 123:339669, 1995.
Meguro, CA 117:69733, 1992.
Al_ousawi, CA 131:199593, 1999.
Al-Mousawi, S.M., et al., “Synthesis of New Condensed 2-Amino-4H-Pyran-3-Carbonitriles and of 2-Aminoquinoline-3-Carbonitriles,”Organic Preparations and Procedures Int.31:305-313, Organic Preparations and Procedures Inc. (1999).
Birch, K.A., et al., “LY290181, an Inhibitor of Diabetes-Induced Vascular Dysfunction, Blocks Protein Kinase C-Stimulated Transcriptional Activation Through Inhibition of Transcription Factor Binding to a Phorbol Response Element,”Diabetes45:642-650, The American Diabetes Association (1996).
Bloxham, J., et al., “Preparation of Some New Benzylidenemalononitriles by an SNAr Reaction: Application to Naphtho[1,2-b]pyran Synthesis,”Heterocycles38:399-408, The Japan Institute of Heterocyclic Chemistry (1994).
Chandrasekhar, S., et al., “Identification of a Novel Chemical Series That Blocks Interleukin-1-Stimulated Metalloprotease Activity in Chrondrocytes,”J. Pharmacol. Exp. Ther.273:1519-1528, The American Society for Pharmacology and Experimental Therapeutics (1995).
Chemical Abstracts, vol. 99, No. 27, Abstract 212393z (1983).
Chemical Abstracts, vol. 125, No. 21, Abstract 265467p (1996).
Elagamey, A.G.A., et al., “Nitriles in Heterocyclic Synthesis: Novel Syntheses of Benzo[b]pyrans, Naphtho[1,2-b]pyrans, Naphtho[2,1-b]pyrans, Pyrano[3,2-h]quinolines and Pyrano[3,2-c]quinolines,”Collection Czechoslovak Chem. Commun.53:1534-1538, Institute of Organic Chemistry and Biochemistry (1988).
Greenwald, R.B., “Drug Delivery Systems Employing 1,4- or 1,6-Elimination: Poly(ethylene glycol) Prodrugs of Amine-Containing Compounds,”J. Med. Chem.42:3657-3667, American Chemical Society (1999).
International Search Report for International Application No. PCT/US02/15401, mailed Sep. 27, 2002.
Klokol, G.V., et al., “Cyclization of Nitriles. XXIII. Addition of Active Phenols to Electron-Deficient Ethylenes, Accompanied by Cyclization to 2-Amino-4H-Benzo[b]pyrans. Crystal Structure of 2-Amino-4-(2-Fluorophenyl)-3-Ethoxycarbonyl-4H-Naphtho[2,1-b]pyran,”J. Org. Chem. USSR23:369-377, Plenum Publishing Corporation (1987).
Leu, Y.-L., et al., “Design and Synthesis of Water-Soluble Glucuronide Derivatives of Camptothecin for Cancer Prodrug Monotherapy and Antibody-Directed Enzyme Prodrug Therapy (ADEPT),”J. Med. Chem.42:3623-3628, American Chemical Society (1999).
Radwan, S.M., et al., “Synthesis and Some Reactions of New Benzo[b]pyran Derivatives,”Phosphorus, Sulfur, and Silicon101:207-211, Gordon and Breach Science Publishers SA (1995).
Sharanin, Yu.A., and Klokol, G.V., “Synthesis of 2-Amino-4H-Chromenes,”J. Org. Chem. USSR19:1582-1583, Plenum Publishing Corporation (1984).
Smith, C.W., et al., “The Anti-Rheumatic Potential of a Series of 2,4-Di-Substituted-4H-Naphtho[1,2-b]pyran-3-Carbonitriles,”Bioorg. Med. Chem. Lett.5:2783-2788, Elsevier Science Ltd. (1995).
Wiernicki, T.R., et al., “Inhibition of Vascular Smooth Muscle Cell Proliferation and Arterial Intimal Thickening by a Novel Antiproliferative Naphthopyran,”J. Pharmacol. Exp. Ther.278:1452-1459, The American Society for Pharmacology and Experimental Therapeutics (1996).
Wood, D.L., et al., “Inhibition of Mitosis and Microtubule Function through Direct Tubulin Binding by a Novel Antiproliferative Naphthopyran LY290181,”Mol. Pharmacol.52:437-444, The American Society for Pharmacology and Experimental Therapeutics (1997).
Pending Non-Provisional U.S. Appl. No. 10/146,139, Cai et al., filed May 16, 2002 (Not Published).
Pending International Patent Application No. PCT/US03/15432, Cai et al., filed May 16, 2003 (Not Published).
Pending International Patent Application No. PCT/US03/15427, Cai et al., filed May 16, 2003 (Not Published).
Robinson, B., Office Communication for U.S. Appl. No. 09/705,840, 17 pages, United States Patent and Trademark Office (mailed Jun. 5, 2001).
Chalker, B.E., Applicants′ Claim Amendments for U.S. Appl. No. 09/705,840, 11 pages, “Amendment And Reply Under 37 C.F.R. § 1.111,” (filed Nov. 5, 2001).
Robinson, B., Office Communication for U.S. Appl. No. 09/705,840, 14 pages, United States Patent and Trademark Office (mailed Jan. 28, 2002).
Chalker, B.E., Applicants′ Claim Amendments for U.S. Appl. No. 09/705,840, 8 pages, “Amendment And Reply Under 37 C.F.R. § 1.111,” (filed Apr. 25, 2002).
Rotman, A., Office Communication for U.S. Appl. No. 09/705,840, 14 pages, United States Patent and Trademark Office (mailed Jul. 12, 2002).
Chalker, B.E., Applicants′ Claim Amendments for U.S. Appl. No. 09/705,840, 4 pages, “Amendment And Reply Under 37 C.F.R. § 1.111,” (filed Dec. 12, 2002).
Chalker, B.E., Applicants′ Claim Amendments for U.S. Appl. No. 09/705,840, 2 pages, “Supplemental Amendment And Reply Under 37 C.F.R. § 1.111,” (filed Mar. 11, 2003).
Robinson, B., Office Communication for U.S. Appl. No. 09/705,840, 14 pages, United States Patent and Trandemark Office (mailed Mar. 25, 2003).
Robinson, B., Office Communication for U.S. Appl. No. 09/705,840, 24 pages, United States Patent and Trademark Office (mailed Jul. 3, 2003).
Esmond, R.W., Applicants′ Claim Amendments for U.S. Appl. No. 09/705,840, 10 pages, “Amendment And Reply Under 37 C.F.R. § 1.111,” (filed Oct. 17, 2003).
Robinson, B., Office Communication for U.S. Appl. No. 09/705,840, 6 pages, United States Patent and Trademark Office (mailed May 18, 2004).
Rao, D.R., Office Communication for United States Patent Application No. 10/146,138, 11 pages, United States Patent and Trademark Office (mailed Aug. 16, 2004.
Walsh, C.J., Applicants'Amendment to the Claims for United States Patent Application No. 10/146,138, 21 pages, “Amendment and Reply Under 37 C.F.R. § 1.111” (filed Dec. 13, 2004).
Rao, D.R., Office Communication for United States Patent Application No. 10/146,138, 9 pages, United States Patent and Trademark Office (mailed Mar. 14, 2005).
Walsh, C.J., Applicants' Amendments to the Claims for United States Patent Application No. 10/146,138, 7 pages “Amendment and Reply Under 37 C.F.R. § 1.116” (filed May 27, 2005).

Affiliated with

Also associated with

Rating

Substituted coumarins and quinolines and analogs as... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted coumarins and quinolines and analogs as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted coumarins and quinolines and analogs as... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3609983